The introduction of the 750mcg parathyroid hormone injection in Australia has encountered limited uptake. Currently, this increased dose medication is mainly intended for individuals with substantial osteoporosis who have been unsuccessful with other medications. Procurement can be challenging due to specialist referral requirements and limited pha